Beclometasone / Formoterol: 4 agencies, 2007–2025
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
The file has been open for more than a decade: 18.1 years separate the first record, 21 Jun 2007 at AWMSG (Wales), from the most recent, 16 Jul 2025 at HAS (France).
PBAC (Australia) changed its position: not recommended in 2020, recommended by 2022, after a resubmission.
No assessment is on file from PHARMAC (New Zealand), TLV (Sweden), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 5 of 20 records date from 2023 or later.
7 distinct indication wordings are recorded for beclometasone / formoterol by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess beclometasone / formoterol, on 21 Jun 2007; PBAC (Australia) did not open a file until 2020 — an unusually long tail of 13.1 years between the earliest and latest system to look at it.
The record arrives in waves: 6 separate years each carry two or more decisions, spread across 9 years in total.
3 of the 4 agencies here assessed beclometasone / formoterol more than once, HAS (France) most often at 10 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed beclometasone / formoterol.
The full ledger for beclometasone / formoterol reads 12 recommended, 5 not assessed, 2 other and 1 not recommended.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 16 Jul 2025 | Listing (Transparency Committee) | SMR moderate · ASMR V | source |
| HAS (France) | 16 Jul 2025 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 24 Jun 2021 | Regular treatment of asthma where use of an inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) combination is a… | outside AWMSG criteria | source |
| PBAC (Australia) | 2020 | Asthma | The PBAC recommended the listing of the fixed dose combination (FDC) of beclometasone (BEC… | source |
| SMC (Scotland) | 7 Jul 2014 | Symptomatic treatment of patients with severe COPD (FEV1 <50% predicted normal) and a history of repeated exacerbations, who have significant symptoms despite regular the… | accepted | source |
15 further decisions for beclometasone / formoterol, across 3 agencies, are not shown here. They link to 10 further source documents.
Related molecules
- budesonide — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- mesalazine — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- beclometasone / formoterol / glycopyrronium — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- prednisolone — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
- betamethasone / calcipotriol — same ATC class A07E — Antidiarrheals / intestinal anti-inflammatories
Coverage: 20 decisions for beclometasone / formoterol from 4 agencies, 2007 to 2025. Data to 7 Sep 2026. ATC class A07E — Antidiarrheals / intestinal anti-inflammatories. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.